Thompson Davis & Co’s Profound Medical PROF Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.4M Sell
215,785
-950
-0.4% -$6.56K 0.93% 14
2025
Q4
$1.71M Buy
216,735
+8,015
+4% +$51.5K 1.02% 13
2025
Q3
$1.02M Sell
208,720
-1,775
-0.8% -$9.06K 0.63% 27
2025
Q2
$1.24M Buy
210,495
+6,645
+3% +$35.1K 0.85% 17
2025
Q1
$1.19M Buy
203,850
+21,555
+12% +$149K 0.94% 14
2024
Q4
$1.37M Buy
182,295
+80,395
+79% +$617K 0.88% 11
2024
Q3
$811K Buy
101,900
+27,100
+36% +$245K 0.6% 26
2024
Q2
$628K Buy
74,800
+6,150
+9% +$49.6K 0.54% 30
2024
Q1
$586K Buy
68,650
+225
+0.3% +$1.88K 0.4% 27
2023
Q4
$581K Sell
68,425
-17,950
-21% -$171K 0.49% 23
2023
Q3
$881K Sell
86,375
-95
-0.1% -$985 1.09% 17
2023
Q2
$1.12M Buy
86,470
+10,875
+14% +$135K 1.27% 13
2023
Q1
$702K Buy
75,595
+4,300
+6% +$49.8K 0.92% 20
2022
Q4
$776K Buy
71,295
+50,709
+246% +$277K 1.1% 15
2022
Q3
$83K Sell
20,586
-3,826
-16% -$25.8K 0.11% 69
2022
Q2
$178K Sell
24,412
-7,287
-23% -$57.6K 0.29% 69
2022
Q1
$285K Sell
31,699
-1,439
-4% -$13.9K 0.35% 62
2021
Q4
$374K Buy
+33,138
New +$414K 0.31% 59

Other funds holding PROF

Thompson Davis & Co's PROF Position: Q1 2026 in Review

Thompson Davis & Co reduced its Profound Medical (PROF) stake by 0.44% in Q1 2026, selling an estimated $6.56K and leaving 215,785 shares worth $1.4M. The position accounts for 0.93% of the portfolio, ranked #14.

Thompson Davis & Co first reported a position in PROF in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.71M in Q4 2025. 57 funds tracked by Wall St. Rank hold PROF as of Q1 2026.

  • Thompson Davis & Co held 215,785 shares of Profound Medical worth $1.4M as of Q1 2026.
  • Thompson Davis & Co sold 950 Profound Medical shares in Q1 2026, an estimated $6.56K.
  • Profound Medical made up 0.93% of Thompson Davis & Co's portfolio in Q1 2026, its #14 holding.
  • Thompson Davis & Co first reported a position in Profound Medical in Q4 2021 and has held it in 18 quarters since.
  • Thompson Davis & Co's Profound Medical position peaked at $1.71M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Profound Medical as of Q1 2026.

Based on Thompson Davis & Co's 13F filing for Q1 2026, filed 16 Apr 2026.